Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/28/24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business UpdateBusiness Wire • 02/28/24
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024Business Wire • 02/21/24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate UpdatesBusiness Wire • 01/08/24
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/24
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary AtresiaBusiness Wire • 12/18/23
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx ConferenceBusiness Wire • 11/20/23
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 11/02/23
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023Business Wire • 10/27/23
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic CholestasisBusiness Wire • 10/17/23
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHANBusiness Wire • 10/07/23
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous XanthomatosisBusiness Wire • 10/02/23
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingBusiness Wire • 09/26/23
Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease FranchiseSeeking Alpha • 09/24/23